Redwood Consultants

Redwood Bioscience is a biotechnology company that developed the SMARTag technology platform, a precision protein-chemical engineering system for the creation of next-generation antibody-drug conjugates (ADCs). The platform utilizes natural post-translational modifications to enable site-specific conjugation, allowing for precise payload positioning and defined stoichiometry that enhances the therapeutic index of biotherapeutics. Founded by Nobel laureate Carolyn Bertozzi and David Rabuka, the company's technology addresses the limitations of traditional ADC conjugation methods by improving potency, safety, and stability. Redwood Bioscience was acquired by Catalent in 2014 and now operates as a core component of Catalent's biologics development and manufacturing services.